Good Sam Club Open Roads Forum: Around the Campfire: 2019–20 CORONAVIRUS PANDEMIC POSTINGS
Open Roads Forum Already a member? Login here.   If not, Register Today!  |  Help

Newest  |  Active  |  Popular  |  RVing FAQ Forum Rules  |  Forum Posting Help and Support  |  Contact  

Search:   Advanced Search

Search only in Around the Campfire

Open Roads Forum  >  Around the Campfire  >  General Topics

 > 2019–20 CORONAVIRUS PANDEMIC POSTINGS

Reply to Topic  |  Subscribe  |  Print Page  |  Post New Topic  | 
Page of 115  
Prev  |  Next
BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 03/02/21 06:50am Link  |  Quote  |  Print  |  Notify Moderator

MEXICOWANDERER wrote:

T cell reactivity? Elapsed time is crucial?


It’s like BioRxiv was waiting for your question. We should keep in mind these are for T cells produced by the original variant or vaccines developed using the sequence of the original variant.

Quote:

Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees.
Preprint: doi: https://doi.org/10.1101/2021.02.27.433180


The emergence of SARS-CoV-2 variants highlighted the need to better understand adaptive immune responses to this virus. It is important to address whether also CD4+ and CD8+ T cell responses are affected, because of the role they play in disease resolution and modulation of COVID-19 disease severity. Here we performed a comprehensive analysis of SARS-CoV-2-specific CD4+ and CD8+ T cell responses from COVID-19 convalescent subjects recognizing the ancestral strain, compared to variant lineages B.1.1.7, B.1.351, P.1, and CAL.20C as well as recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines. Similarly, we demonstrate that the sequences of the vast majority of SARS-CoV-2 T cell epitopes are not affected by the mutations found in the variants analyzed. Overall, the results demonstrate that CD4+ and CD8+ T cell responses in convalescent COVID-19 subjects or COVID-19 mRNA vaccinees are not substantially affected by mutations found in the SARS-CoV-2 variants.


BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 03/02/21 10:49am Link  |  Quote  |  Print  |  Notify Moderator

This preprint covers an evaluation of 1 & 2 doses of the Pfizer vaccine and 1 dose of the AstraZeneca vaccine in 70+ year olds in the UK between Dec 8 2020 and Feb 19 2021 on prevention of symptomatic Covid-19 infections (positive PRC tests), hospitalizations, and deaths. The study found:

Prevention of symptomatic infections:
1 dose of Pfizer was 70% in 80+ year olds
2 doses of Pfizer was 89% in 80+ year olds
1 dose of Pfizer was 61% in 70+ year olds

1 dose of AstraZeneca was 73% in 70+ year olds
2 doses of AstraZeneca has not yet been deployed in the UK

Prevention of hospitalizations:
1 dose of either vaccine was 80% in 70+ year olds

Prevention of deaths:
1 dose of the Pfizer vaccine was 85% effective in 70+ year olds
There wasn't enough data in this time frame to assess AstraZeneca's vaccine

The time frame of this study was when the UK variant was prominent in Britain. I also note that these effectiveness numbers are similar to those reported for the 1 dose J&J vaccine which was tested during the same time frame.

Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England
Preprint: doi: https://doi.org/10.1101/2021.03.01.21252652

MEXICOWANDERER

las peñas, michoacan, mexico

Senior Member

Joined: 06/01/2007

View Profile


Offline
Posted: 03/02/21 11:06am Link  |  Quote  |  Print  |  Notify Moderator

Are there any clinical studies that examine differences of Arthus reaction between the two serums? In the general population in the trials?

Thank you for sharing!

Timmo!

Oregon

Senior Member

Joined: 03/10/2005

View Profile


Offline
Posted: 03/02/21 11:58am Link  |  Quote  |  Print  |  Notify Moderator

Reliable vaccine finder app.

I used it today and it scheduled my first vax for this Friday and second shot on 4/2...at Walgreens.

https://vaccinefinder.org/search/

Moderna and Pfizer-BioNTech COVID Vaccine


(Formerly known as SPRey)
Tim & Sue
Hershey (Sheltie)
2005 F150 4x4 Lariat 5.4L 3.73 Please buy a Hybrid...I need your gas for my 35.7 gallon tank!
2000 Nash 19B...comfortably pimped with a real Queen Size Bed


BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 03/02/21 12:06pm Link  |  Quote  |  Print  |  Notify Moderator

MEXICOWANDERER wrote:

Are there any clinical studies that examine differences of Arthus reaction between the two serums? In the general population in the trials?

Thank you for sharing!


This might have some information for you.

COVID-19 Vaccines: Should We Fear ADE?

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 03/02/21 08:48pm Link  |  Quote  |  Print  |  Notify Moderator

Here is a preprint on testing a GSK/Sanofi vaccine in non human primates based upon virus spike fragments with an adjuvant (same one used in flu vaccines). Two doses provided protection against a viral challenge after vaccination and strong neutralizing titers against the original, UK, and South African variants. (Another clinical trial using products from my employer). This data supports moving into human clinical trials.

Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates
bioRxiv preprint doi: https://doi.org/10.1101/2021.03.02.433390;

* This post was edited 03/02/21 09:02pm by BCSnob *

Deb and Ed M

SW MI & Space Coast, FL USA

Senior Member

Joined: 06/07/2004

View Profile



Posted: 03/03/21 09:25am Link  |  Quote  |  Print  |  Notify Moderator

BCSnob wrote:

Here is a preprint on testing a GSK/Sanofi vaccine in non human primates based upon virus spike fragments with an adjuvant (same one used in flu vaccines). Two doses provided protection against a viral challenge after vaccination and strong neutralizing titers against the original, UK, and South African variants. (Another clinical trial using products from my employer). This data supports moving into human clinical trials.



All good news - some day we'll be awash in vaccines (but we can always share with countries who need it). And "awash with vaccine" is just the way one wants to be during a pandemic.

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 03/04/21 09:52am Link  |  Quote  |  Print  |  Notify Moderator

This study published as a preprint measured the viral loads in symptomatic and asymptotic adults (18-65) and children (<18). The viral loads in symptomatic adults and symptomatic children were similar (~7log10 copies/ml); the viral loads in asymptotic adults and asymptotic children were similar but lower than symptomatic patients (~6log10 copies/ml).

Upper respiratory tract SARS-CoV-2 RNA l........tic and asymptomatic children and adults

MEXICOWANDERER

las peñas, michoacan, mexico

Senior Member

Joined: 06/01/2007

View Profile


Offline
Posted: 03/04/21 01:28pm Link  |  Quote  |  Print  |  Notify Moderator

Average length of maximum communicability between asymptomatic and symptomatic patients. Viral loading seems to be similar. How about span? No "typhoid Mary" syndrome?

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 03/04/21 01:45pm Link  |  Quote  |  Print  |  Notify Moderator

Duration was not evaluated in this study. The information you ask for may not be available.

Quote:

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

Objectives

To summarise the evidence on the detection pattern and viral load of SARS-CoV-2 over the course of an infection (including any asymptomatic or pre-symptomatic phase), and the duration of infectivity.


Methods

A systematic literature search was undertaken in PubMed, Europe PubMed Central and EMBASE from 30 December 2019 to 12 May 2020.


Results

We identified 113 studies conducted in 17 countries. The evidence from upper respiratory tract samples suggests that the viral load of SARS-CoV-2 peaks around symptom onset or a few days thereafter, and becomes undetectable about two weeks after symptom onset; however, viral loads from sputum samples may be higher, peak later and persist for longer. There is evidence of prolonged virus detection in stool samples, with unclear clinical significance.


No study was found that definitively measured the duration of infectivity; however, patients may not be infectious for the entire duration of virus detection, as the presence of viral ribonucleic acid may not represent transmissible live virus.


* This post was edited 03/04/21 01:54pm by BCSnob *

Reply to Topic  |  Subscribe  |  Print Page  |  Post New Topic  | 
Page of 115  
Prev  |  Next

Open Roads Forum  >  Around the Campfire  >  General Topics

 > 2019–20 CORONAVIRUS PANDEMIC POSTINGS
Search:   Advanced Search

Search only in Around the Campfire


New posts No new posts
Closed, new posts Closed, no new posts
Moved, new posts Moved, no new posts

Adjust text size:




© 2021 CWI, Inc. © 2021 Good Sam Enterprises, LLC. All Rights Reserved.